アンデルセン・タウィル症候群市場- 世界の産業規模、シェア、動向、機会、予測、疾患タイプ別、流通チャネル別、地域別、競合市場別、2020-2030F

アンデルセン・タウィル症候群（ATS）の世界市場規模は、2024年に226万米ドルとなり、2030年には349万米ドルに達すると予測され、予測期間中に7.47％の複合年間成長率（CAGR）で成長すると予測されます。

希少遺伝性疾患に対する認識の高まりと診断技術の進歩が、ATS市場への関心を高めています。アンデルセン・タウィル症候群は、骨格筋、心機能、身体発育に影響を与え、しばしば周期性麻痺や生命を脅かす不整脈を引き起こす希少な遺伝性チャネル異常症です。ヘルスケア専門家の間での認知度の向上と遺伝子検査手法の改善により、タイムリーで効果的な疾患管理に不可欠な早期診断が可能となっています。

精密医療と個別化治療戦略の出現は、ATSの標的治療法の開発にさらに影響を及ぼしています。現在の治療選択肢はまだ限られているが、現在進行中のカリウムチャネル調節薬や遺伝子治療に関する研究は大きな可能性を秘めています。ATS患者のアンメットニーズへの対応に注力する製薬企業や研究機関からの投資の増加も、市場の成長に寄与しています。

主な市場促進要因

遺伝子診断の進歩

主な市場課題

複雑な症状による診断の遅れ

このような遅延は、重篤な転帰を防ぐためにタイムリーな介入が不可欠である心臓合併症を伴う症例では特に有害です。

主要市場動向

最先端の遺伝子診断と個別化医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のアンデルセン・タウィル症候群市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 病気の種類別（タイプ1、タイプ2）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 疾患タイプ別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域のアンデルセン・タウィル症候群市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患タイプ別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のアンデルセン・タウィル症候群市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のアンデルセン・タウィル症候群市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のアンデルセン・タウィル症候群市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのアンデルセン・タウィル症候群市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界のアンデルセン・タウィル症候群市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Merck KGA.
• Grevis Pharmaceuticals
• Xeris Pharma
• Novartis AG
• Advanz Pharmaceuticals
• Alembic Pharmaceuticals
• Avet Pharmaceuticals
• Hikma Pharmaceuticals
• Micro Labs
• Advagen Pharma

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Andersen-Tawil Syndrome (ATS) market was valued at USD 2.26 million in 2024 and is projected to reach USD 3.49 million by 2030, growing at a compound annual growth rate (CAGR) of 7.47% during the forecast period.

Rising awareness of rare genetic disorders, coupled with advancements in diagnostic technologies, is propelling interest in the ATS market. Andersen-Tawil Syndrome is a rare genetic channelopathy that impacts skeletal muscles, cardiac function, and physical development, often resulting in periodic paralysis and life-threatening arrhythmias. Increased recognition among healthcare professionals and improvements in genetic testing methodologies are enabling earlier diagnosis, which is critical for timely and effective disease management.

The emergence of precision medicine and personalized therapeutic strategies is further influencing the development of targeted treatments for ATS. Although current treatment options remain limited, ongoing research into potassium channel modulators and gene therapies holds significant promise. Increased investment from pharmaceutical companies and research institutions focused on addressing the unmet needs of ATS patients is also contributing to market growth.

Key Market Drivers

Advancements in Genetic Diagnostics

The growth of the ATS market is strongly supported by progress in genetic diagnostics and electrophysiology, which have significantly enhanced the identification and understanding of this rare autosomal dominant condition. ATS is primarily caused by mutations affecting potassium ion channels, leading to characteristic symptoms including cardiac arrhythmias, muscle weakness, and distinct physical traits. With an estimated prevalence of 0.08 to 0.1 per 100,000 individuals, accurate diagnosis is essential.

Improvements in next-generation sequencing (NGS) and genetic screening techniques have enabled earlier and more precise detection, resulting in better disease management. Reports indicate that approximately 76% of physicians are utilizing genetic testing for rare diseases, reflecting a growing emphasis on early identification.

The integration of artificial intelligence (AI) into diagnostic workflows is accelerating the identification of rare mutations associated with ATS, facilitating tailored treatment strategies. Furthermore, the development of rare disease registries and patient databases is enriching the collective understanding of disease progression and treatment efficacy. Regulatory support for orphan drug development and accelerated approval pathways is also fostering innovation in therapy development for ATS.

Key Market Challenges

Diagnostic Delays Due to Complex Symptomatology

A primary challenge in the ATS market lies in diagnostic delays, driven by the condition's varied and often ambiguous symptom presentation. Patients may exhibit a broad range of clinical manifestations, including cardiac arrhythmias, episodes of muscle paralysis, and unique facial features-symptoms that, while indicative of ATS, are not exclusive to it.

This clinical variability frequently leads to misdiagnoses, as symptoms may be mistaken for more common cardiac or neuromuscular conditions. Consequently, patients often receive inappropriate treatments that fail to address the underlying genetic cause.

Furthermore, limited awareness of ATS among both the general public and healthcare professionals exacerbates diagnostic delays. Due to the rarity of the condition, physicians may not consider ATS early in the diagnostic process, resulting in prolonged patient journeys involving multiple specialists and extensive testing before a definitive diagnosis is reached.

These delays can be particularly detrimental in cases involving cardiac complications, where timely intervention is essential to prevent severe outcomes.

Key Market Trends

Cutting-Edge Genetic Diagnostics and Personalized Care

Technological advancements in genetic diagnostics-particularly next-generation sequencing (NGS) and whole exome sequencing (WES)-are revolutionizing the diagnosis and management of ATS. These techniques enable the rapid and accurate identification of pathogenic mutations, including those in the KCNJ2 and CACNA1S genes, which are commonly associated with ATS.

As a result, clinicians can now deliver faster, more accurate diagnoses, facilitating timely intervention and access to appropriate treatments. These developments have also deepened scientific understanding of ATS at the molecular level, allowing researchers to explore genotype-phenotype relationships and identify novel therapeutic targets.

This expanding knowledge base is supporting the development of more effective, genetically informed treatments and is accelerating progress toward personalized medicine approaches in the ATS space. Moreover, genetic diagnostics are increasingly being used for carrier screening among family members, enabling early detection, proactive monitoring, and preventative care-further driving demand for ATS-related medical services and diagnostics.

Key Market Players

• Merck KGA.
• Grevis Pharmaceuticals
• Xeris Pharma
• Novartis AG
• Advanz Pharmaceuticals
• Alembic Pharmaceuticals
• Avet Pharmaceuticals
• Hikma Pharmaceuticals
• Micro Labs
• Advagen Pharma

Report Scope:

In this report, the Global Andersen-Tawil Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Andersen-Tawil Syndrome Market, By Disease Type:

• Type 1
• Type 2

Andersen-Tawil Syndrome Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Andersen-Tawil Syndrome Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Andersen-Tawil Syndrome Market.

Available Customizations:

Global Andersen-Tawil Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Andersen-Tawil Syndrome Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Disease Type (Type 1, Type 2)
  • 4.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.3. By Region
  • 4.2.4. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Disease Type
  • 4.3.2. By Distribution Channel
  • 4.3.3. By Region

5. Asia Pacific Andersen-Tawil Syndrome Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type
  • 5.2.2. By Distribution Channel
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Andersen-Tawil Syndrome Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Disease Type
      • 5.3.1.2.2. By Distribution Channel
  • 5.3.2. India Andersen-Tawil Syndrome Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Disease Type
      • 5.3.2.2.2. By Distribution Channel
  • 5.3.3. Australia Andersen-Tawil Syndrome Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Disease Type
      • 5.3.3.2.2. By Distribution Channel
  • 5.3.4. Japan Andersen-Tawil Syndrome Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Disease Type
      • 5.3.4.2.2. By Distribution Channel
  • 5.3.5. South Korea Andersen-Tawil Syndrome Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Disease Type
      • 5.3.5.2.2. By Distribution Channel

6. Europe Andersen-Tawil Syndrome Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Andersen-Tawil Syndrome Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Germany Andersen-Tawil Syndrome Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Spain Andersen-Tawil Syndrome Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Distribution Channel
  • 6.3.4. Italy Andersen-Tawil Syndrome Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease Type
      • 6.3.4.2.2. By Distribution Channel
  • 6.3.5. United Kingdom Andersen-Tawil Syndrome Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease Type
      • 6.3.5.2.2. By Distribution Channel

7. North America Andersen-Tawil Syndrome Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Andersen-Tawil Syndrome Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Mexico Andersen-Tawil Syndrome Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. Canada Andersen-Tawil Syndrome Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Distribution Channel

8. South America Andersen-Tawil Syndrome Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Andersen-Tawil Syndrome Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. Argentina Andersen-Tawil Syndrome Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Colombia Andersen-Tawil Syndrome Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Distribution Channel

9. Middle East and Africa Andersen-Tawil Syndrome Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Andersen-Tawil Syndrome Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Saudi Arabia Andersen-Tawil Syndrome Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. UAE Andersen-Tawil Syndrome Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Andersen-Tawil Syndrome Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Merck KGA.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Grevis Pharmaceuticals
• 14.3. Xeris Pharma
• 14.4. Novartis AG
• 14.5. Advanz Pharmaceuticals
• 14.6. Alembic Pharmaceuticals
• 14.7. Avet Pharmaceuticals
• 14.8. Hikma Pharmaceuticals
• 14.9. Micro Labs
• 14.10. Advagen Pharma

15. Strategic Recommendations

16. About Us & Disclaimer